When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

In a new study published in Nature, scientists from Gladstone Institutes and UC San Francisco (UCSF) focused on T cells and ...

Feng Zhang, James and Patricia Poitras Professor in Neuroscience, MIT, to serve as Vice Chairman ...